Boehringer receives breakthrough therapy designation for spesolimab
Pharmaceutical Technology
MAY 3, 2023
Boehringer Ingelheim managing directors board member and human pharma head Carinne Brouillon stated: “GPP flares may appear suddenly, intensify quickly, and can be life-threatening if left untreated, leaving those affected feeling anxious and uncertain about their future.
Let's personalize your content